[ad_1]
Agreement number two is in the box.
The European Commission announced on Friday that the company has formally signed a second agreement to purchase a corona vaccine.
The company has signed an agreement that guarantees the EU up to 300 million doses of the subunit vaccine developed by the two companies Sanofi and GSK (GlaxoSmithKline).
Norway is part of the EU scheme and receives one percent of the vaccines the EU receives.
The two companies have already entered into agreements for the sale of 100-500 million doses to the United States and 60 million doses to the United Kingdom.
A long time until it comes
There is still a long way to go before a possible corporate vaccine appears:
The vaccine has just entered a combined phase 1/2 study and the hope is that they will begin the crucial phase 3 study by the end of the year.
– If everything goes as it should and the vaccine is approved, companies hope to have a vaccine ready by the second half of 2021, the EU writes in a press release.
The companies aim for a production capacity of 1 billion doses per year.
Part of the agreement is a donation scheme where vaccines can be administered to the COVAX global vaccine program.
The vaccine is based on the vaccine technology called Subenhet in Norwegian, and is a further development of one of Sanofi’s flu vaccines. In a subunit vaccine, all of the virus in the vaccine uses, but a small part, a small part of the virus that will teach the body to recognize and attack the virus if it becomes infected.
Also read: The largest pharmaceutical group in the world: the vaccine will probably be ready before Christmas
Various ongoing agreements
This is the second agreement signed by the EU. The first was with AstraZeneca, which expects to deliver vaccines starting in December.
In addition, the EU has signed letters of intent with Johnson & Johnson, CureVac, Moderna and BioNTech / Pfizer.
These last two companies are the two that the United States has expressed its hope that they can begin delivering vaccines as early as in the October / November monthly magazine.
Also read: Three vaccines struggle to get approved first: favorites can create additional challenges
[ad_2]
